• BioMarin Pharmaceutical Inc., of Novato, Calif., said it completed a Phase I study of BMN-111, an analogue of C-type natriuretic peptide, for achondroplasia, the most common form of human dwarfism.
To continue reading subscribe now to BioWorld Today
